Breaking News Instant updates and real-time market news.

PCG

PG&E

$22.55

0.82 (3.77%)

, NFLX

Netflix

$381.72

5.6 (1.49%)

09:55
07/09/19
07/09
09:55
07/09/19
09:55

Early notable gainers among liquid option names on July 9th

Notable gainers among liquid option names this morning include PG&E (PCG) $22.74 +1.01, Netflix (NFLX) $383.73 +7.67, Edwards Lifesciences (EW) $189.02 +2.33, First Solar (FSLR) $67.45 +0.82, and Eli Lilly (LLY) $112.76 +1.25.

PCG

PG&E

$22.55

0.82 (3.77%)

NFLX

Netflix

$381.72

5.6 (1.49%)

EW

Edwards Lifesciences

$187.85

1.17 (0.63%)

FSLR

First Solar

$66.85

0.21 (0.32%)

LLY

Eli Lilly

$112.94

1.44 (1.29%)

  • 17

    Jul

  • 30

    Jul

  • 09

    Sep

  • 16

    Sep

  • 02

    Oct

PCG PG&E
$22.55

0.82 (3.77%)

07/01/19
MZHO
07/01/19
NO CHANGE
MZHO
Buy
Mizuho views changes to California bill as 'constructive' for state utilities
Early Friday morning the California Senate released their changes to AB 1054 which addresses the wildfire risk for each of the state's utilities, Mizuho analyst Paul Fremont tells investors in a research note. The analyst views the changes as "constructive" for the California utilities. Utilities will fund $7.5B of the $18B Wildfire Mitigation fund, and will be able to get recovery, but not a return on, $5B worth of wildfire mitigation capital expenditures, the analyst points out. Further, until PG&E (PCG) emerges from bankruptcy, which is expected in March 2020, the Wildfire Mitigation Fund will only pay out 40% of allowed claims, adds Fremont. He keeps a Buy rating on Edison International (EIX) and Neutral rating on PG&E.
06/28/19
WOLF
06/28/19
DOWNGRADE
WOLF
Peer Perform
PG&E downgraded to Peer Perform from Outperform at Wolfe Research
06/21/19
MSCO
06/21/19
NO CHANGE
MSCO
Equal Weight
California proposal only a 'partial fix' for PG&E, says Morgan Stanley
After Bloomberg reported yesterday that California Governor Gavin Newsom is encouraging the state's legislature to adopt several of the Wildfire Commission's recommendations, including a liquidity fund seeded by at least $10B in Department of Water Resources bonds and $7.5B in utility equity contributions, Morgan Stanley analyst Stephen Byrd said he thinks the plan outlined in the report is only a "partial fix" and would not be satisfactory for large institutional equity investors, for whom some type of cap on future liability is critical. The analyst, who thinks long-term investors will likely require more steps than those outlined in the Bloomberg report before buying PG&E shares, keeps an Equal Weight rating on the stock.
06/20/19
BOFA
06/20/19
UPGRADE
Target $13
BOFA
Neutral
Bloom Energy upgraded to Neutral from Underperform at BofA/Merrill
BofA Merrill Lynch analyst Julien Dumoulin-Smith upgraded Bloom Energy (BE) to Neutral from Underperform as he sees shares being supported by shifting trends in its core California markets amid proactive deenergizations by PG&E (PCG) as well as more broadly across the U.S. East Coast. Following a call with Generac (GNRC) that pointed to a meaningful inflection in California customers' demand for stand-by generators, the analyst expects increased demand for Bloom's micro-grid solution, he said. He also thinks the increased focus and need for reliability with the 5G build-out for major telecom companies will support demand for Bloom products, the analyst added. He has a $13 price target on Bloom Energy shares.
NFLX Netflix
$381.72

5.6 (1.49%)

07/09/19
NEED
07/09/19
NO CHANGE
NEED
Hold
Disney battle with Netflix in OTT to be 'expensive', says Needham
Needham analyst Laura Martin keeps her Hold rating on Disney (DIS), saying that while the valuation on the stock has gapped up based on investor expectations of it "winning" the OTT battle, she believes that it will take longer for the company to "displace" Netflix (NFLX) and beat the other competitors in the space. The analyst raises her FY20 revenue estimates to $83.4B from $76.6B to account for the contribution of the new Fox assets, but also lowers her EPS view by 15c to $6.39 to reflect the higher investments tied to Disney's OTT service, as the management will have to incur higher TV production costs due to digital platform competition coming from "Netflix, Hulu, Amazon (AMZN) Video, etc."
07/09/19
COWN
07/09/19
NO CHANGE
Target $455
COWN
Outperform
Netflix Original programming hours seen up 52% y/y, says Cowen
Cowen analyst John Blackledge maintained an Outperform rating and $455 price target on Netflix ahead of the company's second quarter earnings on July 17. In a research note to investors, Blackledge says he expects "solid" results, with Original programming hours up 52% year over year serving as a tailwind. Additionally, the analyst says his firm's latest U.S. survey data suggests about 51% of Netflix users will watch "Stranger Things" Season 3 and many lapsed users may resubscribe, possibly driving gross additions at the end of Q2 and into the third quarter.
07/02/19
RHCO
07/02/19
NO CHANGE
RHCO
SunTrust expects in-line Q2 results for Netflix with upside to Q3
SunTrust analyst Matthew Thornton maintained a Buy rating and $402 price target on Netflix ahead of the company's Q2 earnings report, which is scheduled for July 17 after the close. The analyst sees Q2 results being in-line, and sees Q3 guidance being above consensus estimates. Thornton also expects Netflix to reiterate its prior margin and cash flow guidance. He sees his 2019 thesis in-tact and the firm's model is unchanged.
06/27/19
PIPR
06/27/19
NO CHANGE
Target $440
PIPR
Overweight
Netflix shares can rally 50% over next 12-18 months, says Piper Jaffray
Netflix has "significant room" to grow subscribers based on various ways of slicing the company's total addressable market, Piper Jaffray analyst Michael Olson tells investors in a research note. The analyst has historically used fixed broadband households as the Netflix addressable market, but he now believes this is "too limiting" given the potential for mobile-first and mobile-only users to adopt the service, especially outside of the U.S. When looking at current Netflix adoption as a percentage of internet or pay-TV households, Olson sees international "significantly" lagging domestic, suggesting potential for "dramatic" international growth in the coming years. While consensus estimates assume a high rate of ongoing international sub growth, "relatively more aggressive scenarios" have a realistic chance of playing out, Olson tells investors in a research note. Looking to 2021, the analyst believes investor anticipation around potential for greater than 20% penetration of Netflix across global internet households could lead to a ~50% move in the stock over the next 12-18 months. Olson keeps an Overweight rating on Netflix shares with a $440 price target. The stock closed yesterday up $1.90 to $362.20.
EW Edwards Lifesciences
$187.85

1.17 (0.63%)

04/24/19
JEFF
04/24/19
NO CHANGE
Target $210
JEFF
Buy
Edwards Lifesciences price target raised to $210 from $195 at Jefferies
Jefferies analyst Raj Denhoy raised his price target for Edwards Lifesciences to $210 from $195 saying the company remains well positioned for 10%-plus growth following its Q1 results. He sees 2019 as "another big year" in transcather therapies and keeps a Buy rating on the shares.
04/15/19
FBCO
04/15/19
NO CHANGE
Target $221
FBCO
Outperform
Edwards Lifesciences price target raised to $221 from $189 at Credit Suisse
Credit Suisse analyst Matt Miksic raised his price target for Edwards Lifesciences to $221 from $189, while reiterating an Outperform rating on the shares. his bullish outlook is based in part on his view that the company does not yet reflect the low-risk expansion of the TAVR market, and investors appear likely to look past Q1 results toward evidence over the next few quarters of increased TAVR growth following the LR data.
03/27/19
JPMS
03/27/19
NO CHANGE
Target $190
JPMS
Neutral
Edwards Lifesciences price target raised to $190 from $175 at JPMorgan
JPMorgan analyst Robbie Marcus raised his price target for Edwards Lifesciences to $190 from $175 and keeps a Neutral rating on the shares. The analyst says his doctor survey following the Annual Scientific Session is "very bullish" and supportive of "significant" transcatheter aortic valve replacement market growth in the U.S. Marcus expects TAVR volume growth to accelerate from 15% in 2018 to 19% in 2019 and 22% in 2020. Nonetheless, he remains Neutral on shares of Edwards at current valuation levels. The analyst wants to see evidence of a faster than expected acceleration in the U.S. market, or less share/price loss to competition before looking to revisit his rating.
03/27/19
ADAM
03/27/19
NO CHANGE
Target $215
ADAM
Buy
CMS' TAVR coverage memo positive for Edwards Lifesciences, says Canaccord
Canaccord analyst Jason Mills reiterated a Buy rating on Edwards Lifesciences with a $215 price target, telling investors in a research note that he views the Centers for Medicare and Medicaid Services' proposed Transcatheter Aortic Valve Replacement decision memo as incrementally positive for the TAVR field in general, and an incremental positive for Edwards specifically. The new, proposed TAVR coverage memo, which Mills says is less stringent on specific, prior procedure requirements, updates the requirements for TAVR centers to maintain their status as a TAVR center, and requires the center perform at least 50 AVRs/year, including at least 20 TAVRs/year, or else at least 100 AVRs every two years, at least 40 of which need to be TAVR.
FSLR First Solar
$66.85

0.21 (0.32%)

05/03/19
UBSW
05/03/19
NO CHANGE
Target $73
UBSW
Buy
First Solar sentiment to improve on earnings ramp, says UBS
UBS analyst Jon Windham kept his Buy rating and $73 price target on First Solar after its Q1 results, saying the company's maintained guidance in spite of the Q1 earnings miss sets it up for an "aggressive sequential earnings ramp." The analyst believes that EPS growth is supported by First Solar's "ramping 3rd party Series 6 shipments" as well as declining start-up expense and expects investor sentiment on the stock to improve.
05/03/19
ARGS
05/03/19
NO CHANGE
Target $66
ARGS
Buy
First Solar price target raised to $66 from $60 at Argus
Argus analyst David Coleman raised his price target on First Solar to $66 and kept his Buy rating after its raised FY19 revenue outlook, saying the company is well positioned in the solar industry given its "positive cash flow, solid balance sheet, and focus on cadmium telluride technology." The analyst also believes that First Solar is attractively valued at 22.1-times his expected 2019 earnings, which is around the middle of the 4.5- to 37.7-times historical average range and below the peer median of 26.3-times.
05/06/19
JPMS
05/06/19
NO CHANGE
Target $72
JPMS
Overweight
JPMorgan adds First Solar to Focus List, boosts target to $72
JPMorgan analyst Paul Coster added First Solar to his firm's Analyst Focus List and raised his price target for the shares to $72 from $70. The company's Q1 results indicate it is heading toward a "strong earnings inflection" on the back of the Series 6 ramp, and this is not fully priced into the stock, Coster tells investors in a research note. He sees potential upside to 2020 earnings estimates and views First Solar as a near-term idea. Coster keeps an Overweight rating on the shares.
06/13/19
BARD
06/13/19
NO CHANGE
Target $75
BARD
Outperform
First Solar selloff yesterday on tariff news a buying opportunity, says Baird
Baird analyst Ben Kallo recommends using yesterday's pullback in shares of First Solar as a buying opportunity. The shares were under pressure yesterday after the U.S. Trade Representative announced bifacial and other "specialty" solar panels would be exempt from Section 201 solar tariffs, Kallo tells investors in a research note. However, the analyst thinks the fundamental impact of the exemption will be minimal on First Solar given its long-term contracts. As such, he views the news as largely headline risk. First Solar remains a top idea for Kallo, who keeps an Outperform rating on the shares with a $75 price target.
LLY Eli Lilly
$112.94

1.44 (1.29%)

06/11/19
JPMS
06/11/19
NO CHANGE
JPMS
Overweight
Eli Lilly Rewind data missed 'fairly high' expectations, says JPMorgan
JPMorgan analyst Chris Schott is not surprised by the weakness yesterday in shares of Eli Lilly as he believes the Rewind data came in below "fairly high" expectations. However, the analyst ultimately sees the data confirming a cardiovascular benefit for Trulicity and supporting "continued strong Trulicity/GLP-1 uptake." Further, Schott sees the tirzepatide data at the American Diabetes Association conference as continuing to highlight a potentially best in class efficacy profile for the product. Lilly remains the analyst's top pick in his pharma coverage.
06/11/19
LEHM
06/11/19
UPGRADE
LEHM
Equal Weight
Novo Nordisk upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Emmanuel Papadakis upgraded Novo Nordisk (NVO) to Equal Weight from Underweight and raised his price target for the shares to 325 kronor from 275 kronor. The analyst views competitor updates at the American Diabetes Association conference, specifically from Eli Lilly (LLY), as "underwhelming."
05/30/19
WELS
05/30/19
NO CHANGE
WELS
U.S. generic data continues to show challenging environment, says Wells Fargo
Wells Fargo analyst David Maris says that according to April IQVIA data, Teva (TEVA) U.S. generic sales were down 19% in April year over year, while brands sales were down 15%. Additionally, according to IQVIA data, Teva recently ceded its second place U.S. prescription market share place to competitor Eli Lilly (LLY) for its migraine drug, Ajovy, he points out. For Mylan (MYL), Maris says the monthly trends also paint a negative picture, with IQVIA U.S. generic sales in April down 36%. Nonetheless, the analyst believes Teva and Mylan shares seem to be reflecting an "aggressively negative outlook" given the current earnings multiples, and setting aside the worst-case outcomes in the opioid and price fixing cases, these may be at or nearing attractive valuations. However, for now, he remains on the sidelines, and within generics, continues to recommend Outperform-rated Amphastar (AMPH).
05/28/19
GSCO
05/28/19
INITIATION
Target $135
GSCO
Buy
Eli Lilly initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Eli Lilly with a Buy rating and $135 price target. The company has new product cycles in four large and growing therapeutic categories - diabetes, cancer, pain and immunology, Flynn tells investors in a research note. He believes investors are underappreciating Eli Lilly's longer-term growth potential in diabetes.

TODAY'S FREE FLY STORIES

TCEHY

Tencent

$0.00

(0.00%)

, MDLA

Medallia

$37.09

(0.00%)

07:31
07/21/19
07/21
07:31
07/21/19
07:31
On The Fly
Opening Day: Start-up DouYou becomes China's biggest Wall Street IPO of 2019 »

Drugmaker Genmab raised…

TCEHY

Tencent

$0.00

(0.00%)

MDLA

Medallia

$37.09

(0.00%)

MIRM

Mirum Pharmaceuticals

$13.51

0.17 (1.27%)

FULC

Fulcrum Therapeutics

$12.49

-0.99 (-7.34%)

PHR

Phreesia

$24.01

-1.15 (-4.57%)

GMAB

Genmab

$18.06

-0.14 (-0.77%)

AMK

AssetMark Financial

$27.71

0.39 (1.43%)

ORCC

Owl Rock

$15.51

0.11 (0.71%)

DOYU

DouYu

$10.50

-0.51 (-4.63%)

NOVA

Sunnova Energy

$0.00

(0.00%)

CSTL

Castle Biosciences

$0.00

(0.00%)

WSG

Wanda Sports

$0.00

(0.00%)

LVGO

Livongo Health

$0.00

(0.00%)

HCAT

Health Catalyst

$0.00

(0.00%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 24

    Jul

  • 31

    Jul

  • 14

    Aug

  • 09

    Sep

  • 16

    Sep

  • 15

    Oct

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

PYPL

PayPal

$118.65

-1.22 (-1.02%)

, V

Visa

$179.18

-1.34 (-0.74%)

08:31
07/20/19
07/20
08:31
07/20/19
08:31
Periodicals
MasterCard, Visa among best stocks to play fintech boom, Barron's says »

The fintech units within…

PYPL

PayPal

$118.65

-1.22 (-1.02%)

V

Visa

$179.18

-1.34 (-0.74%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 30

    Jul

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

, SBNY

Signature Bank

$123.87

1.07 (0.87%)

08:28
07/20/19
07/20
08:28
07/20/19
08:28
Periodicals
KeyCorp, U.S. Bancorp better positioned for Fed rate cut, Barron's says »

KeyCorp (KEY), Signature…

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

SBNY

Signature Bank

$123.87

1.07 (0.87%)

KEY

KeyCorp

$17.45

0.15 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

  • 16

    Oct

CMG

Chipotle

$746.80

-17.43 (-2.28%)

08:24
07/20/19
07/20
08:24
07/20/19
08:24
Periodicals
Chipotle stock made 'stunning' comeback, Barron's says »

Chipotle's stock is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Sep

BYND

Beyond Meat

$176.65

6.28 (3.69%)

07:40
07/20/19
07/20
07:40
07/20/19
07:40
Periodicals
Beyond Meat could spike after earnings, Barron's says »

After rising so…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

NFLX

Netflix

$315.10

-10.04 (-3.09%)

07:37
07/20/19
07/20
07:37
07/20/19
07:37
Periodicals
Netflix's problems have only just begun, Barron's says »

Netflix has a problem and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, TGT

Target

$88.02

-0.48 (-0.54%)

07:34
07/20/19
07/20
07:34
07/20/19
07:34
Periodicals
Time to aim higher on Target's stock, Barron's says »

As retailers have…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

TGT

Target

$88.02

-0.48 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 21

    Aug

  • 19

    Sep

  • 25

    Sep

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, FDX

FedEx

$167.08

1.69 (1.02%)

07:31
07/20/19
07/20
07:31
07/20/19
07:31
Periodicals
FedEx ups game amid e-commerce growth, Barron's says »

It is time to embrace…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

FDX

FedEx

$167.08

1.69 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 17

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

07:27
07/20/19
07/20
07:27
07/20/19
07:27
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

ORCL

Oracle

$57.55

-0.58 (-1.00%)

AZN

AstraZeneca

$40.11

-0.61 (-1.50%)

BMY

Bristol-Myers

$43.32

-0.72 (-1.63%)

LLY

Eli Lilly

$106.75

-1.57 (-1.45%)

GSK

GlaxoSmithKline

$40.97

-0.44 (-1.06%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

MRK

Merck

$81.39

-1.28 (-1.55%)

NVS

Novartis

$93.58

-0.715 (-0.76%)

PFE

Pfizer

$42.78

-0.28 (-0.65%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$41.94

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 30

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

  • 02

    Sep

  • 09

    Sep

  • 16

    Sep

  • 16

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 02

    Oct

  • 15

    Oct

  • 04

    Nov

BHVN

Biohaven Pharmaceutical

$44.16

-0.61 (-1.36%)

18:12
07/19/19
07/19
18:12
07/19/19
18:12
Hot Stocks
Biohaven receives CRL from FDA for application seeking NURTEC approval »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

CE

Celanese

$107.01

0.9 (0.85%)

18:01
07/19/19
07/19
18:01
07/19/19
18:01
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

F

Ford

$10.20

-0.06 (-0.58%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Periodicals
Ford plans to lay off 185 employees at Ontario plant, Reuters reports »

A union local said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 23

    Oct

RTN

Raytheon

$178.55

2.45 (1.39%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Hot Stocks
Raytheon awarded $191.01M Air Force contract modification »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UTX

United Technologies

$132.37

1.08 (0.82%)

17:44
07/19/19
07/19
17:44
07/19/19
17:44
Hot Stocks
United Technologies awarded $253.71M Air Force contract »

United Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LMT

Lockheed Martin

$356.90

0.675 (0.19%)

17:40
07/19/19
07/19
17:40
07/19/19
17:40
Hot Stocks
Lockheed Martin awarded $1.47B Missile Defense Agency contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ARES

Ares Management

$28.13

-0.305 (-1.07%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Syndicate
Breaking Syndicate news story on Ares Management »

Ares Management files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 06

    Aug

HAFC

Hanmi Financial

$21.68

-0.105 (-0.48%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Hot Stocks
Hanmi Financial to delay release of Q2 results »

Hanmi Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PAYS

Paysign

$17.49

-0.48 (-2.67%)

17:32
07/19/19
07/19
17:32
07/19/19
17:32
Syndicate
Breaking Syndicate news story on Paysign »

Paysign files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$43.19

0.83 (1.96%)

17:28
07/19/19
07/19
17:28
07/19/19
17:28
Hot Stocks
Methanex reaches final investment decision on methanol plant in Geismar, LA »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

17:17
07/19/19
07/19
17:17
07/19/19
17:17
Conference/Events
Credit Suisse biotech analysts to hold an analyst/industry conference call »

Biotech Analysts provide…

17:14
07/19/19
07/19
17:14
07/19/19
17:14
Conference/Events
UBS retail/hardlines analyst to hold an analyst/industry conference call »

Retail/Hardlines Analyst…

SHIP

Seanergy Marine

$0.64

-0.0425 (-6.25%)

17:05
07/19/19
07/19
17:05
07/19/19
17:05
Hot Stocks
Seanergy Maritime receives noncompliance notice from Nasdaq »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONM

Sonim

$13.42

0.24 (1.82%)

16:41
07/19/19
07/19
16:41
07/19/19
16:41
Conference/Events
Sonim management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 12

    Sep

KINS

Kingstone Companies

$8.81

0.09 (1.03%)

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Hot Stocks
Kingstone names Barry Goldstein CEO »

Kingstone Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Options
Preliminary option volume of 22.6M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.